Conduit Pharmaceuticals Files 8-K on Shareholder Nominations
Ticker: CDTTW · Form: 8-K · Filed: Sep 6, 2024 · CIK: 1896212
| Field | Detail |
|---|---|
| Company | Conduit Pharmaceuticals Inc. (CDTTW) |
| Form Type | 8-K |
| Filed Date | Sep 6, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001, $11.50 |
| Sentiment | neutral |
Sentiment: neutral
Topics: shareholder-nomination, governance, corporate-action
Related Tickers: CDT
TL;DR
Conduit Pharma (CDT) filed an 8-K for shareholder nominations - potential shake-up incoming.
AI Summary
Conduit Pharmaceuticals Inc. filed an 8-K on September 6, 2024, to report shareholder nominations pursuant to Exchange Act Rule 14a-11. The company, formerly known as Murphy Canyon Acquisition Corp. until November 30, 2021, is incorporated in Delaware and headquartered in San Diego, California.
Why It Matters
This filing indicates potential changes or activism within Conduit Pharmaceuticals' shareholder base, which could influence the company's future direction and governance.
Risk Assessment
Risk Level: medium — Shareholder nominations can signal internal disputes or a push for strategic changes, introducing uncertainty.
Key Players & Entities
- Conduit Pharmaceuticals Inc. (company) — Registrant
- Murphy Canyon Acquisition Corp. (company) — Former company name
- September 6, 2024 (date) — Filing date
- Delaware (jurisdiction) — State of incorporation
- San Diego, California (location) — Business address
FAQ
What is the specific purpose of the shareholder nominations being reported in this 8-K?
The 8-K filing states that the purpose is to report shareholder nominations pursuant to Exchange Act Rule 14a-11.
When was Conduit Pharmaceuticals Inc. formerly known as Murphy Canyon Acquisition Corp.?
Conduit Pharmaceuticals Inc. was formerly known as Murphy Canyon Acquisition Corp. until November 30, 2021.
In which state is Conduit Pharmaceuticals Inc. incorporated?
Conduit Pharmaceuticals Inc. is incorporated in Delaware.
What is the business address of Conduit Pharmaceuticals Inc.?
The business address of Conduit Pharmaceuticals Inc. is 4995 Murphy Canyon Road, Suite 300, San Diego, California.
What is the filing date of this Current Report on Form 8-K?
The date of the report, and the earliest event reported, is September 6, 2024.
Filing Stats: 595 words · 2 min read · ~2 pages · Grade level 11.5 · Accepted 2024-09-06 17:00:15
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share CDT The Nasdaq
- $11.50 — of Common Stock at an exercise price of $11.50 CDTTW The Nasdaq Stock Market LLC
Filing Documents
- form8-k.htm (8-K) — 40KB
- 0001493152-24-035334.txt ( ) — 262KB
- cdt-20240906.xsd (EX-101.SCH) — 4KB
- cdt-20240906_def.xml (EX-101.DEF) — 29KB
- cdt-20240906_lab.xml (EX-101.LAB) — 36KB
- cdt-20240906_pre.xml (EX-101.PRE) — 27KB
- form8-k_htm.xml (XML) — 6KB
08 Shareholder Director Nominations
Item 5.08 Shareholder Director Nominations. The Board of Directors (the "Board") of Conduit Pharmaceuticals Inc. (the "Company") previously established October 2, 2024 as the date for its 2024 Annual Meeting of Stockholders (the "Annual Meeting"). The Board has determined it is in the best interests of the Company's stockholders to postpone the previously scheduled Annual Meeting. The Board of the Company has now established December 18, 2024, as the date for the Annual Meeting. The Board also established October 25, 2024, as the record date for the Annual Meeting. Due to the fact that the Company did not hold an annual meeting of stockholders in 2023, the Company is providing the due date for submission of any qualified stockholder proposal or director nominations. In accordance with Rule 14a-5(f) and Rule 14a-8(e) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and the Company's bylaws (the "Bylaws"), the deadline for receipt of stockholder proposals or nominations for inclusion in the Company's proxy statement for the Annual Meeting pursuant to Rule 14a-8 will be no later than September 16, 2024. Stockholder proposals must comply with all of the applicable requirements set forth in the rules and regulations of the Securities and Exchange Commission, including Rule 14a-8 under the Exchange Act and the Bylaws.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: September 6, 2024 CONDUIT PHARMACEUTICALS INC. By: /s/ Dr. David Tapolczay Name: Dr. David Tapolczay Title: Chief Executive Officer